# Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction

> **NCT03549494** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 45 (actual)

## Conditions studied

- Stomach Neoplasm
- Gastrointestinal Neoplasms
- Digestive System Neoplasm
- Esophageal Neoplasms
- Head and Neck Neoplasms
- Gastrointestinal Disease
- Digestive System Disease
- Esophageal Diseases
- Stomach Diseases
- Esophagogastric Junction Disorder

## Interventions

- **DIETARY_SUPPLEMENT:** Ocoxin-Viusid®

## Key facts

- **NCT ID:** NCT03549494
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2022-06-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03549494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03549494, "Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03549494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*